display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced - esophageal cancer (mEC)
mEC - (neo)adjuvant (NA)
anti-PD-(L)1
nivolumab based treatment
nivolumab alone CheckMate 577

Study type: